PECAM1 and prostate cancer: The present research established a subcutaneous prostate cancer-bearing model (Figure 1A), and ligustilide significantly reduced the expression levels of α-SMA and CD31 in tumor tissue, which represented CAFs and vascular endothelial cells, respectively (Figure 1B).